Literature DB >> 10601919

Positive cone biopsy specimen margins in women infected with the human immunodeficiency virus.

L A Boardman1, J F Peipert, J W Hogan, A S Cooper.   

Abstract

OBJECTIVES: The purpose of this study was to compare the positive margin rate associated with cervical conization among women who are seropositive for human immunodeficiency virus with that among women who are seronegative. STUDY
DESIGN: This was a cross-sectional study of 245 women who underwent cervical conization for the following indications: biopsy-proven cervical intraepithelial neoplasia grade 2 or 3, abnormal endocervical curettage specimen, cytologic-histologic examination discrepancy, persistent cervical intraepithelial neoplasia grade 1, or abnormal cytologic characteristics with inadequate colposcopic examination.
RESULTS: Twenty-two (47.8%) of 46 women who were seropositive for human immunodeficiency virus and 65 (32.7%) of 199 women who were seronegative had positive cone biopsy specimen margins. In a multivariable logistic regression the human immunodeficiency virus-seropositive women had a 2-fold increased risk of having a positive cone biopsy margin (odds ratio, 2.25; 95% confidence interval, 1.07-4.76).
CONCLUSION: If the presence of positive cone biopsy specimen margins represents the potential for disease progression, then our findings of a positive margin rate of nearly 50% in a human immunodeficiency virus-positive population may argue against the kind of conservative management of colposcopic follow-up that has been proposed for immunocompetent women.

Entities:  

Mesh:

Year:  1999        PMID: 10601919     DOI: 10.1016/s0002-9378(99)70382-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women.

Authors:  Laura L Reimers; Susan Sotardi; David Daniel; Lydia G Chiu; Anne Van Arsdale; Daryl L Wieland; Jason M Leider; Xiaonan Xue; Howard D Strickler; David J Garry; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2010-10       Impact factor: 5.482

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.